Neuland Laboratories Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Neuland Laboratories kazanç ve gelirinin sırasıyla yıllık 33.9% ve 23.3% oranında artması tahmin edilirken, EPS'nin yıllık 33.8% oranında büyümesi bekleniyor.
Anahtar bilgiler
33.9%
Kazanç büyüme oranı
33.8%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 17.9% |
| Gelir büyüme oranı | 23.3% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 07 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09
Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Recent updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 3/31/2027 | 26,113 | 6,340 | N/A | N/A | 2 |
| 3/31/2026 | 21,750 | 4,976 | 3,569 | 4,369 | 2 |
| 3/31/2025 | 15,901 | 3,229 | 2,773 | 3,512 | 2 |
| 9/30/2024 | 15,283 | 2,797 | 413 | 2,457 | N/A |
| 6/30/2024 | 16,352 | 3,361 | N/A | N/A | N/A |
| 3/31/2024 | 15,586 | 3,001 | 1,175 | 2,612 | N/A |
| 12/31/2023 | 15,809 | 3,171 | N/A | N/A | N/A |
| 9/30/2023 | 14,574 | 2,662 | 2,444 | 3,192 | N/A |
| 6/30/2023 | 13,333 | 2,154 | N/A | N/A | N/A |
| 3/31/2023 | 11,915 | 1,635 | 1,711 | 2,372 | N/A |
| 12/31/2022 | 10,406 | 1,008 | N/A | N/A | N/A |
| 9/30/2022 | 10,078 | 831 | 341 | 1,070 | N/A |
| 6/30/2022 | 9,720 | 651 | N/A | N/A | N/A |
| 3/31/2022 | 9,517 | 638 | -373 | 604 | N/A |
| 12/31/2021 | 9,400 | 593 | N/A | N/A | N/A |
| 9/30/2021 | 9,489 | 731 | 359 | 1,437 | N/A |
| 6/30/2021 | 9,324 | 742 | N/A | N/A | N/A |
| 3/31/2021 | 9,370 | 806 | 840 | 1,894 | N/A |
| 12/31/2020 | 8,852 | 540 | N/A | N/A | N/A |
| 9/30/2020 | 8,436 | 384 | 96 | 887 | N/A |
| 6/30/2020 | 7,884 | 257 | N/A | N/A | N/A |
| 3/31/2020 | 7,640 | 162 | 85 | 573 | N/A |
| 12/31/2019 | 7,443 | 321 | N/A | N/A | N/A |
| 9/30/2019 | 7,120 | 257 | 312 | 899 | N/A |
| 6/30/2019 | 6,945 | 216 | N/A | N/A | N/A |
| 3/31/2019 | 6,675 | 164 | 68 | 699 | N/A |
| 3/31/2018 | 5,284 | 121 | N/A | 113 | N/A |
| 3/31/2017 | 5,789 | 469 | N/A | 387 | N/A |
| 3/31/2016 | 5,100 | 273 | N/A | 448 | N/A |
| 3/31/2015 | 4,692 | 159 | N/A | 132 | N/A |
| 3/31/2014 | 4,657 | 268 | N/A | 488 | N/A |
| 12/31/2013 | 4,619 | 258 | N/A | 545 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: NEULANDLAB 'nin tahmini kazanç büyümesi (yıllık 33.9% ) tasarruf oranının ( 6.7% ) üzerindedir.
Kazançlar ve Piyasa: NEULANDLAB şirketinin kazançlarının (yıllık 33.9% ) Indian pazarından (yıllık 17.9% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: NEULANDLAB şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: NEULANDLAB şirketinin gelirinin (yıllık 23.3% ) Indian pazarından (yıllık 10.4% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: NEULANDLAB şirketinin gelirinin (yıllık 23.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: NEULANDLAB 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok